Transfusion related acute lung injury (TRALI)
1Department of Anesthesiology, Reanimatology and Intensive Care University Hospital Zagreb
2,Croatian Institute of Transfusion Medicine Hospital Transfusion Service in Clinical
DOI: 10.22514/SV42.102009.1 Vol.4,Issue 2,October 2009 pp.8-11
Published: 28 October 2009
Transfusion-related acute lung injury (TRALI) is a complication following transfusion of blood products and is potentially a life-threatening adverse event of transfusion. The first case of fatal pulmonary edema following transfusion was reported in the 1950s. In recent time, TRALI has developed from an almost unknown transfusion reaction to the most common cause of transfusion related major morbidities and fatalities. A clinical definition of TRALI was established in 2004, based on acute respiratory distress which has temporal association with transfusion of blood components. In 2008 a distinction between classic and delayed syndrome was proposed. However, pathophysiology of TRALI still remains controversial. A number of different models were proposed to explain the pathogenesis. The two, presently most accepted models, are not mutually exclusive. The first is the antibody mediated model and the second is the two-event model.
In this review article the definition of TRALI, patient predisposition, treatment, prevention and reporting guidelines are exa-mined. The current knowledge on the topic TRALI is summarized.
transfusion, acute lung injury
TAJANA ZAH,JASNA MESARIĆ,VIŠNJA MAJERIĆ-KOGLER. Transfusion related acute lung injury (TRALI). Signa Vitae. 2009. 4(2);8-11.
3. Graul A, Heiden M, Gräf K, Keller-Stanislawski B. Hämovigilanz in Deutschland – Berichte an das Paul-Ehrlich-Institut über Verdachtsfälle von Transfusionsreaktionen im Beobachtungszeitraum Januar 1995 bis Dezember 2002.Transfus Med Hemother 2003;30:232–8.
4. Joergensen J, Taaning E. DART – a volunteer system of haemovigillance in Denmark. Transfusion Alternatives. Transfus Med 2003;5:260–4.
5. Robillard P, Nawej KI, Chapdeleine A, Poole J, Garneau N. Adverse transfusion reactions with respiratory signs and symptoms including TRALI in the Quebec Haemovigillance system: 2000–2003.Transfusion 2004;44:23-9.
6. Barnard RD. Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity reactions NY State. J Med 1951;51:2399–402.
7. Popovsky MA, Abel MP, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis 1983;128:185–9.
8. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion- related acute lung injury. Transfusion 1985;25(6):573-7.
9. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001;41:264–8.
10. Toy P, Popovsky MA. Transfusion-related acute lung injury: Definition and review. Crit Care Med 2005;33:721–6.
11. Silliman CC, Paterson AJ, Dickey WO, Stroneck DF, Popovsky MA, Caldwell SA, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: A retrospective study. Transfusion 1997;37:719–26.
12. Wallis JP, Lubenko A, Wells AW, Chapman CE. Single hospital experience of TRALI. Transfusion 2003; 43:1053–9.
13. Silliman CC, Boskkov L, Mehdizadehkashi, Elzi DJ, Dickey WO, Podlosky L, et al. Transfusion related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003;101:454-62.
14. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards and under-standing of TRALI. Transfus Med Rev 2005;19:2–31.
15. Jawa RS, Anillo S, Kulaylat MN. Transfusion-Related Acute Lung Injury. J Int Care Med 2008;23(2):109-21.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.